

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

Jan Wolff^{1,2,3}, Pamela Reißner⁴, Gudrun Hefner⁵, Claus Normann², Klaus Kaier⁶, Harald Binder⁶, Christoph Hiemke⁷, Sermin Toto⁸, Katharina Domschke², Michael Marschollek¹, Ansgar Klimke^{4,9}

1 Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Germany. **2** Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. **3** Evangelical Foundation Neuerkerode, Germany. **4** Vitos Hochtaunus, Friedrichsdorf, Germany. **5** Vitos Clinic for Forensic Psychiatry, Eltville, Germany **6** Institute of Medical Biometry and Statistics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany. **7** Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany. **8** Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany. **9** Heinrich-Heine-University Düsseldorf, Germany.

Correspondence Dr. Jan Wolff, Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover, Germany. Address: Karl-Wiechert-Allee 3, 30625 Hannover. Email: janwolff123@gmail.com, wolff.jan@mh-hannover.de, ORCID: <https://orcid.org/0000-0003-2750-0606>

Key words (MeSH) Depression, Polypharmacy, Antidepressants, Hospitals, Drug Interactions, Psychiatry

Abstract

Introduction The aim of this study was to analyse prescription patterns and the determinants of drug-drug interactions (DDI) and potentially inappropriate medication (PIM) in pharmacotherapy of depressive disorders.

Methods Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019.

Results The study included 14,418 inpatient cases. The mean number of drugs per day was 3.7 (psychotropic drugs = 1.7; others = 2.0). Thirty-one percent of cases received at least five drugs simultaneously (polypharmacy). Almost one half of all cases received a combination of multiple antidepressant drugs (24.8%, 95% CI 24.1% - 25.5%) or a treatment with antidepressant drugs augmented by antipsychotic drugs (21.9%, 95% CI 21.3% - 22.6%). The most frequently used antidepressants were selective serotonin reuptake inhibitors, followed by serotonin and norepinephrine reuptake inhibitors and tetracyclic antidepressants. In multivariate analyses, cases with recurrent depressive disorders and cases with severe depression were more likely to receive a combination of multiple antidepressant drugs (Odds ratio recurrent depressive disorder: 1.56, 95% CI 1.41 - 1.70, severe depression 1.33, 95% CI 1.18 - 1.48). The risk of any DDI and PIM in elderly patients increased substantially with each additional drug (Odds Ratio: DDI 1.32, 95% CI: 1.27 - 1.38, PIM 1.18, 95% CI: 1.14 - 1.22) and severity of disease (Odds Ratio per point on CGI-Scale: DDI 1.29, 95% CI: 1.11 - 1.46, PIM 1.27, 95% CI: 1.11 - 1.44), respectively.

Conclusion This study identified potential sources and determinants of safety risks in pharmacotherapy of depressive disorders and provided additional data which were previously unavailable. Most inpatients with depressive disorders receive multiple psychotropic and non-psychotropic drugs and DDI and PIM are relatively frequent. Patients with a high number of different drugs must be intensively monitored in the management of their individual drug-related risk-benefit profiles.

Introduction

Depressive disorders were the third leading cause of global non-fatal burden of disease in 2017 [1]. Pharmacotherapy is an important component in the treatment of depressive disorders [2]. Common guidelines recommend monotherapy with second generations antidepressants, i.e. selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) and other drugs that selectively target neurotransmitters [3–5]. The majority of patients fail to achieve remission after first monotherapy with antidepressants [6]. Several second-step treatments are recommended in guidelines, such as switching to a different monotherapy, augmentation with antipsychotics or combining two antidepressants [4,5,7].

The combination of multiple antidepressants and the combination with other drugs bear the risk of drug-drug-Interactions (DDI). DDI are a frequent cause of adverse drug reactions (ADR) [8]. The number of simultaneously taken drugs is one of the strongest risk factors for DDI and potentially inappropriate medication (PIM) in the elderly [9]. DDI are a relevant aspect in the treatment of patients with depressive disorders, for instance, via metabolism by the cytochrome P450 enzyme group (pharmacokinetic) and the combination of multiple anticholinergics or QT-interval prolonging drugs (pharmacodynamic).

Cytochrome P450 (CYP) enzymes are essential for the phase 1 metabolism of drugs and most pharmacokinetic DDI in the treatment of depressive disorders are the results of inhibition or induction of CYP enzymes [10]. Many drugs for the treatment of depressive disorders have strong anticholinergic effects in connection with their biochemical mechanisms, such as tricyclic antidepressants [11,12]. Drug-induced

prolongation of the QT interval is associated with an increased risk of a rare but potentially fatal form of cardiac arrhythmia, so-called "torsade de pointes" (TdP), [13].

A prolongation of the QT interval has been shown for several antidepressants, in particular tricyclic antidepressants and the SSRIs (es-) citalopram [14,15].

An increased risk of ADR was found with the simultaneous use of more than one anticholinergic [16] and QT interval prolonging drug [17]. Pharmacokinetics and -dynamics change in elderly patients due to the progressive decline in the functional reserve of multiple organs and systems with an influence on drug disposition when aging [18]. Therefore, many drugs are considered inappropriate for the elderly [19–21]. Medication is considered as PIM if risks outweigh benefits of better alternatives [22].

The pharmacological treatment of depressive disorders is complex and the associated DDI and PIM can impair patient outcomes and increase costs [23]. The aim of this study was to investigate prescription patterns and the determinants of DDI and PIM in pharmacotherapy of depressive disorders.

Methods

Data

Our study included all inpatient cases with a main diagnosis in the group of depressive episodes (F32*, ICD-10) or recurrent depressive disorders (F33*) who were consecutively discharged from eight psychiatric hospitals between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. These hospitals belong to a common health care provider that provides about one half of all inpatient psychiatric services in Hesse, Germany.

We used daily medication data for each included inpatient obtained from the electronic medical records at the study sites. Thereby, we were able to investigate the medications for each day separately and to include all treatment modifications of during a hospital stay. The present study was part of a larger pharmacovigilance project funded by the German Innovation Funds (OSA-PSY - Optimization of inpatient drug therapy for mental illnesses, grant number 01VSF16009). The study was approved by the ethics committee of the State Medical Association of Hesse under the file number FF116 / 2017. The present study analysed a sub-sample of patients with depressive disorders. Previous publications from this research project can be found in the reference list [10,12,14,21,24,25].

The study investigated 1) pharmacokinetic DDI via CYP enzyme inducing and inhibiting drugs and the respective victim drugs, 2) pharmacodynamic DDI via the administration of more than one anticholinergic drug and 3) pharmacodynamic DDI via administration of more than one drug that potentially prolongs the QT-interval. In addition, the administration of PIM to patients over the age of 64 years was investigated.

CYP-mediated drugs were identified in accordance to the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology [26], restricted to inhibitions and inductions that lead to decrease or increase of plasma concentrations of victim drugs by more than 50%, respectively. In addition, melperone [27], levomepromazine [28] and perazine [29–31] were considered as CYP inhibitors. Additional non-psychotropic victim drugs were added based on CYP substrate properties defined by Hiemke and Eckermann [32]. In total, these sources resulted in covering the following isoforms for analyses of CYP-mediated DDI: CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4.

QT interval prolonging drugs were identified based on the lists of Hiemke and Eckermann [32], Wenzel-Seifert and Wittmann [15] and the drugs listed with known or possible risk for TdP by Arizona Center for Education and Research on Therapeutics (AZCERT) [33,34]. Anticholinergic activity of drugs was identified according to Hiemke and Eckermann, Chew et al. and Lertxundi et al. [32,35,36]. PIM were identified according the German list of medications that are potentially inappropriate in elderly patients, the so-called Priscus-list [19].

Analyses

The groups N05 and N06 of the Anatomical-Therapeutic-Chemical (ATC) classification, respectively, were defined as psychotropic drugs [37]. Drugs classified in group N06A were defined as antidepressants. Drugs classified in group N05A were defined as antipsychotics. Dietetics and food supplements, homeopathic preparations and anthroposophic medicine and only locally applied active ingredients were excluded. We defined polypharmacy as the simultaneous use of at least five different pharmaceuticals [38], averaging over the entire hospital stay.

Arithmetic means and standard deviations were calculated as measures of central tendency and dispersion, respectively. Medians and interquartile ranges were calculated for variables with skewed distributions or a relevant number of outliers. Confidence intervals for proportions were calculated according to Agresti and Coull [39]. We used multivariate logistic regression models to explain the relationship between patient-specific characteristics and type of antidepressant treatment and the risk of DDI and PIM.

Results

The study included 14,418 inpatient cases from eight psychiatric hospitals (Table 1). About 61% of total cases had a main diagnosis in the group recurrent depressive disorders (F33*) and 39% in the group of depressive episodes (F32*). Thirty-one percent of cases received at least 5 drugs simultaneously (polypharmacy).

Tab 1 Description of included cases.

Number of cases	14,418	
Female (Number, % of total per column)	8,307	58
Age at admission (in years, mean and standard deviation)	48	18
Length of stay (in days, mean and standard deviation)	29	14 to 46
Day-clinic (Number of cases, % of total per column)	4,159	29
Number of comorbidities (median and interquartile range)	2	1 to 3
Main diagnosis (Number of cases, % of total per column)		
(F32.0) Mild depressive episode	14	0
(F32.1) Moderate depressive episode	1,573	11
(F32.2) Severe depressive episode without psychotic symptoms	3,538	25
(F32.3) Severe depressive episode with psychotic symptoms	475	3
(F32.8) Other depressive episodes	22	0
(F32.9) Depressive episode, unspecified	22	0
(F33.0) Recurrent depressive disorder, current episode mild	21	0
(F33.1) Recurrent depressive disorder, current episode moderate	2,509	17
(F33.2) Recurrent depressive disorder current episode severe without psychotic symptoms	5,613	39
(F33.3) Recurrent depressive disorder current episode severe with psychotic symptoms	605	4
(F33.4) Recurrent depressive disorder, currently in remission	13	0
(F33.8) Other recurrent depressive disorders	7	0
(F33.9) Recurrent depressive disorder, unspecified	6	0
Number of psychotropic drugs per day (mean and standard deviation)	1.7	1.1
Number of non-psychotropic drugs per day (mean and standard deviation)	2.0	2.5
Polypharmacy (Number, % of total per column)	4,413	31

Interquartile range shows the values of the 25th and 75th percentiles. Polypharmacy: At least five different drugs simultaneously.

A total of 96 different psychotropic and 619 different non-psychotropic drugs were administered during the study period. The mean number of different drugs per patient during an inpatient episode was 5.6 (psychotropic drugs = 2.7; others = 2.9). The mean daily number of drugs was 3.7 (psychotropic drugs = 1.7; others = 2.0) per case. Figure 1 shows the distribution of the number of different drugs per treatment day broken down by severity of disease and main diagnoses groups. The mean number of drugs were higher for severe cases than for moderate cases in both depressive episodes and recurrent disorders.

Fig 1 Number of different drugs per day. Boxes show the range between the 25th percentile and the 75th percentile. The horizontal line within the boxes shows the median. The numbers in squares show the arithmetic mean.

Antidepressants were by far the most frequently used drug group, with 85% of cases with recurrent depressive disorders and 73% depressive episodes receiving at least one drug from this group (Figure 2), followed by antipsychotic drugs.

Fig 2 TOP 10 drug groups. ATC-Code are provided in brackets. Acid Related Dis.: Drugs for acid related disorders, Antithrombotic: Antithrombotic agents, Antianemic: Antianemic preparations, Beta Blocking: Beta blocking agents, Renin-Angiotensin Sys.: Agents acting on the renin-angiotensin System, Antiinfla. & -rheum.: Antiinflammatory and antirheumatic products, Hypnotics & Sedat.: Hypnotics and sedatives.

Figure 3 shows how frequent and in which combinations antidepressant and antipsychotic drugs were used. Almost one half of all cases received a combination of multiple antidepressant drugs (24,8%, 95% CI 24,1% - 25.5%) or a treatment with antidepressant drugs augmented by antipsychotic drugs (21,9%, 95% CI 21,3% - 22.6%). The most frequently used antidepressants were selective serotonin reuptake inhibitors (SSRI), followed by serotonin and norepinephrine reuptake inhibitors (SNRI) and tetracyclic antidepressants (Figure 3 B). SSRI were the drug class which was most frequently used for monotherapy (12% of inpatient days, Figure 3 A). The most frequent augmentation therapy was SSRI augmented by atypical antipsychotics,

followed by SNRI augmented by atypical antipsychotics. The most frequent combinations of antidepressants were SSRI in combination with tetracyclic antidepressants and SNRI in combination with the tetracyclic antidepressant mirtazapine. Figure 3 shows only drug combinations that accounted for at least 2% of total patient days. Lithium did not reach that threshold. In total, 2.8% of patients received Lithium alone or in combination with other drugs for at least one day.

Fig 3 Frequency of antidepressant and antipsychotic drugs and their combinations.

(A+B) Augmentation: Combination of antidepressant and antipsychotic drugs. Combination AD: Combination of more than one antidepressant drug. Combination AP: Combination of more than one antipsychotic drug. Mono: Use of a single antidepressant or antipsychotic drug. None: Neither an antidepressant drug nor an antipsychotic drug. **(A)** Number of days with the respective drug or drug combination and the proportion in total patient days. Only intersections with at least 2% of total days are shown. SSRI: Selective serotonin reuptake inhibitors, atyp. AP: atypical antipsychotics, SNRI: Serotonin and norepinephrine reuptake inhibitors, mid-low AP: middle- and low-potency antipsychotics. None: Patient did not receive an antidepressant or an antipsychotic drug at that day. NDRI: Norepinephrine–dopamine reuptake inhibitor **(B)** Total number of days with the respective drug and the proportion in total patient days. Double counting of days is possible. Combinations are counted within and between classes of antidepressants and antipsychotics. **(C)** Total number of cases with the respective treatment regime and proportion in total cases. None: Patient did not receive an antidepressant or an antipsychotic drug. Mono AD: Patient received one antidepressant drug. Switch/Trial: Patient received more than one antidepressant or antipsychotic drug but not more than three days in combination. Combi AD: Patient received more than one antidepressant drug in combination more than three days. Augmentation AD/AP: Patient received a combination of antidepressant and antipsychotic drugs more than three days. Only AP: Patient received antipsychotic drugs but no antidepressant drugs.

Cases with moderate depression and cases with depressive episodes (F32) were more likely to receive neither antidepressant nor antipsychotic drug treatment and more likely to receive a monotherapy with antidepressants (Table 2). Cases with recurrent depressive disorders and cases with severe depression were more likely to receive a combination of multiple antidepressant drugs. Cases with a high severity of disease measured by the CGI-scale at both admission and discharge were more likely to have switched between different antidepressant or antipsychotic drugs.

Table 2: Logistic regression models on the probability of receiving different antidepressant or and antipsychotic drug treatments.

	None			Mono AD			Switch/Trial			Combi AD			Only AP			Augmentation AD/AP		
	Odds Ratio	95% CI		Odds Ratio	95% CI		Odds Ratio	95% CI		Odds Ratio	95% CI		Odds Ratio	95% CI		Odds Ratio	95% CI	
Day clinic	2.10	1.81	2.39	1.96	1.75	2.18	0.61	0.33	0.89	0.87	0.77	0.96	0.62	0.50	0.74	1.11	0.73	1.48
Sex (female)	0.95	0.84	1.07	1.05	0.95	1.15	1.09	0.82	1.36	1.09	0.99	1.19	0.83	0.71	0.96	0.96	0.76	1.16
Age (10 y.)	0.78	0.75	0.81	0.98	0.95	1.01	1.07	0.89	1.24	1.22	1.19	1.25	0.80	0.76	0.83	0.95	0.81	1.09
<i>Main diag. (Ref: F32)</i>																		
(F33) Recurrent depr. dis.	0.52	0.46	0.58	0.81	0.73	0.89	1.16	0.88	1.44	1.56	1.41	1.70	0.83	0.71	0.95	0.86	0.69	1.04
<i>Severity (Ref: Moderate)</i>																		
Severe	0.52	0.45	0.58	0.74	0.66	0.82	0.95	0.64	1.25	1.33	1.18	1.48	1.03	0.85	1.21	1.56	1.11	2.00
Mild/Other	1.00	0.40	1.60	0.90	0.42	1.39	0.49	0.00	1.22	0.83	0.33	1.34	1.62	0.44	2.80	1.61	0.21	3.00
Number of comorbidities	0.91	0.88	0.94	0.93	0.90	0.95	0.99	0.96	1.03	0.99	0.97	1.01	1.11	1.08	1.14	1.02	0.99	1.05
CGI admission	0.87	0.80	0.95	0.92	0.85	0.98	1.25	1.03	1.47	1.02	0.95	1.09	1.03	0.92	1.14	1.08	0.92	1.23
CGI discharge	0.88	0.83	0.94	0.94	0.90	0.99	1.17	1.05	1.29	1.10	1.06	1.15	0.97	0.90	1.04	0.98	0.90	1.07
Length of stay	0.97	0.96	0.97	0.99	0.99	0.99	0.99	0.99	1.00	1.02	1.02	1.02	0.98	0.98	0.99	1.00	1.00	1.00

None: Patient did not receive an antidepressant or an antipsychotic drug. Mono AD: Patient received one antidepressant drug. Switch/Trial: Patient received more than one antidepressant or antipsychotic drug but not more than three days in combination. Combi AD: Patient received more than one antidepressant drug in combination therapy more than three days. Only AP: Patient received antipsychotic drugs but no antidepressant drugs. Augmentation AD /AP: Patient received a combination of antidepressant and antipsychotic drugs more than three days. CI: Confidence interval. Age (10 y.): Coefficient per ten years of age. Recurrent depr. dis.: Recurrent depressive disorder, CGI: Clinical Global Impression Scale

The number of simultaneously used drugs influenced the risk of DDI and PIM, as illustrated in Figure 4. The steepest increase and the highest overall risk were found in pharmacodynamic DDI related to the combination of multiple QT-prolonging drugs.

Fig 4 Mean number of drugs per day and the proportion of cases with at least one DDI or PIM during their stay CYP450-Interaction: Pharmacokinetic cytochrome P450 (CYP)-mediated drug-drug interaction. QT-Combi.: A combination of at least two drugs on the same day with known or possible risk of TdP. Antichol. Combi.: A combination of at least two drugs on the same day with at least moderate anticholinergic activity. PIM: Potentially inappropriate medication in the elderly. >64: Number of cases of more than 64 years of age at admission.

A relatively large fraction of total cases of DDI and PIM was accounted for by certain drugs and their combinations. Avoiding these drugs could lead to a substantial reduction of overall cases, as shown in Figure 5.

Fig 5 TOP-20 drugs and drug combinations ranked by proportion of affected cases in total number of cases Double counting is possible, i.e. a case can have received several drugs or combinations of drugs. CYP450-Interaction: Pharmacokinetic cytochrome P450 (CYP)-mediated drug-drug interaction. QT-Combi.: A combination of at least two drugs on the same day with known/high or possible/moderate risk of TdP. Antichol. Combi.: A combination of at least two drugs on the same day with at least moderate anticholinergic activity. PIM: Potentially inappropriate medication in the elderly. Poss: Possible. Mod: Moderate.

Figure 6 shows the results of a logistic regression on the occurrence of at least one DDI and PIM during a patient stay at the hospital. The odds ratios shown in the circles reflect the multiplicative effect, e.g. the risk for receiving at least one PIM increased by 18% for each additional drug taken, controlled for the other variables in the model. Another important risk factor was severity of disease, represented by the admission score on the Clinical Global Impressions (CGI)-Scale. The risk of any DDI increased with each additional drug by 32% (Odds Ratio: 1.32, 95% CI: 1.27 - 1.38) and with each additional point at the CGI-scale by 29% (Odds Ratio: 1.29, 95% CI: 1.11 - 1.46) (not shown in Figure 6).

Fig 6 Patient-specific risk factors for DDI and PIM Circles show odds ratios of a multivariate logistic regression. These ratios reflect the multiplicative effect per influencing variable, i.e., for example, the risk of receiving at least one PIM increased by 18% for each additional drug taken, controlled for the other variables in the model. The values in brackets show the 95% confidence interval. Confidence intervals that do not include 1 show a statistically significant effect. CYP450-Interaction: Pharmacokinetic cytochrome P450 (CYP)-mediated drug-drug interaction. QT-Combi.: A combination of at least two drugs on the same day with known or possible risk of TdP. Antichol. Combi.: A combination of at least two drugs on the same day with at least moderate anticholinergic activity. PIM: Potentially inappropriate medication in the elderly. Mod.: Moderate.

Discussion

Main findings

This study examined prescription patterns, DDI, PIM and their determinants in depressive disorders. Almost one half of all cases received a combination of multiple antidepressant drugs or a treatment with antidepressant drugs augmented by antipsychotic drugs. Cases with recurrent depressive disorders and cases with severe depression were more likely to receive a combination of multiple antidepressant drugs. DDI and PIM were frequent in patients with depressive disorders, and the main risk factors were the number of simultaneously taken drugs and severity of disease. Relatively few drugs accounted for a large proportion of total DDI and PIM.

Clinical implications

Psychiatric hospital care must focus on pharmacovigilance due to patients' frequent exposure to long-term poly-pharmacotherapy, poor compliance to pharmacological treatment and co-morbidity with organic illnesses requiring the prescription of multiple drugs [40]. Pharmacoepidemiologic data about prescription patterns can help to clarify potential sources of safety risks and focus on relevant aspects of drug treatment [41]. This study has added important data on this issue that were previously unavailable. Antidepressant drugs were the most frequently used pharmacotherapy in our study. The effectiveness of antidepressants in the treatment of depressive disorders has been

firmly established by previous research. A recent review investigated more than 500 trials and concluded that all of 21 studied antidepressants were more efficacious than placebo in adults with major depressive disorders [42]. Accordingly, antidepressant monotherapy is recommended as first line therapy for patients with a diagnosis of depressive disorders in current guidelines [5].

The present study found that 13% of cases with depressive disorders neither received antidepressant nor antipsychotic drugs. Cases with moderate depression and cases with depressive episodes were more likely to receive neither antidepressants nor antipsychotic drugs than patients with severe depression and recurrent depressive disorders, respectively. Guidelines recommend antidepressants in exceptional cases for patients with mild depression, generally for moderate depression and especially for patients with severe depression [43]. However, while the benefit of antidepressants over placebo was found to be substantial in severe depression, effects may be minimal or nonexistent, on average, in patients with mild or moderate symptoms [44,45]. In addition to less severe symptoms, there are other potential reasons for a hospital treatment without antidepressants, such as patients' refusal to take the medication [46]. When antidepressant treatment is not indicated or possible or failed, several alternative strategies for treatment exist [47], such as cognitive-behavioral psychotherapy [48], or in severe cases electroconvulsive therapy [49] and vagus nerve stimulation [50].

Almost one half of all cases received a combination of multiple antidepressant drugs or a treatment with antidepressant drugs augmented by antipsychotic drugs. Several studies suggested that combining multiple antidepressants after failed monotherapy can be effective [51]. Our study found that tetracyclic antidepressants, in our study only mirtazapine, were the drug class used most frequently for combination therapy with

SSRI, which is supported by current guidelines [5]. Moreover, we found relatively frequent combinations of mirtazapine with SNRI, which were shown to be effective by several studies but are currently not included in clinical guidelines [52–56]. The combination of multiple antidepressants could be advantageous in comparison to switching antidepressants as there is no need for titration and initial improvements might be maintained [57]. However, a combination strategy requires more attention to potential DDI and PIM.

About 22% of patients received treatment with antidepressants augmented by antipsychotic drugs. The most frequent augmentation was conducted with atypical antipsychotics. Atypical antipsychotics were found to be effective as augmentation in major depressive disorders but also associated with an increased risk of discontinuation due to adverse events [58]. Therefore, current guidelines for the treatment of unipolar depression recommend augmentation therapy with the atypical antipsychotics only if previous monotherapy with antidepressant drugs failed [5]. However, not all antipsychotics were necessarily administered to address depressive disorders. Instead, they might have been used to address insomnia [59,60], control agitation and aggressive behaviour [61] or to treat comorbid psychotic symptoms. Augmentation therapy was identified to be superior to monotherapy with either antidepressant or antipsychotic drugs and to placebo in the acute treatment of psychotic depression [62,63], which accounted for 7.4% of our total sample (see Table 1). Furthermore, Lithium is recommended for augmentation therapy in unipolar depression by current guidelines [5]. Its relevant effects include recurrence prevention, acute-antidepressant effects and anti-suicidal effects. However, Lithium was used less frequently than other drugs in our study (2.8% of both total patient days and hospital cases).

We identified relatively few cases with a switch from one antidepressant drug to another. This result is in agreement with current studies that found that, following non-efficacy with an initial SSRI, only about one fifth of hospital cases remit and more than a half do not show a substantial benefit after a second-step switch to another monoaminergic antidepressant drug [64]. Furthermore, three reviews illustrated that the effectiveness of switching between drug classes does not significantly differ from the switch within drug classes [65–67].

Combination and augmentation strategies increase the risk for DDI and PIM. DDI and PIM do not necessarily lead to ADR and negative patient outcomes. However, the association between undesired DDI and PIM and an increased risk of negative patient outcomes has been firmly established by previous studies [8, 16, 17, 68–72]. Indeed, the association between DDI and actual negative patient outcomes might often be underestimated in psychiatry and therefore neglected in clinical practice [73].

Negative outcomes can be caused, for instance, by reduced or increased drug serum or plasma concentration, e.g. leading to the loss of desired drug effects or stronger ADR, respectively. In clinical practice, increased awareness of potential sources of DDI and PIM can help medical staff to achieve desired and avoid undesired therapeutic outcomes [74]. Patients with multiple simultaneously administered drugs and patients requiring drugs with a narrow therapeutic range warrant close therapeutic drug monitoring to hold the patients' exposure within the desired therapeutic window [75]. The present study has quantified the problem, added an overview of the relevant risk factors and listed the main drugs and combination drug therapies accounting for potential DDI and PIM in hospital psychiatry.

The present study in comparison to previous research

The comparison of the present results to previous research was limited by scarce data considering pharmacoepidemiology of psychiatric hospital care for depressive disorders. The present study discerned most inpatients with depressive disorders to receive multiple psychotropic and non-psychotropic drugs. Rhee and Rosenheck found that 58% of depressed adults in their sample from office-based psychiatric care received more than one psychotropic drug simultaneously [76]. This number was slightly lower than the number in the present total sample (65%, not shown in Figures). However, in addition to the different settings, i.e. office-based versus inpatient treatment, a further explanation might be that Rhee and Rosenheck only considered the first 8 items per prescription for their analysis, while in the present study all pharmaceuticals were included.

Cascade et al. investigated the prevalence of antidepressant monotherapy versus combinations and found that 85% of patients treated by office-based physicians received antidepressant monotherapy [77]. This is contrast to the results of our study, which found that almost half of all cases received either a combination of multiple antidepressants or an augmentation with antipsychotics. However, the study by Cascade et al was carried out at office-based physicians and the prevalence of monotherapy decreased with increased severity of disease. Furthermore, psychiatrists (32%) were more likely to use a combination of multiple antidepressant drugs than primary care physicians (8%) and this is more similar to the percentage of cases that received an antidepressant combination therapy in the present study (25%). Augmentation therapy with antipsychotics was administered in only 2% of regimens in the study of Cascade et al published in 2007, which was far less than in the present study. However, Lenderts et al investigated the trends in pharmacotherapy of

depressive disorders in 2009 after the approval of an atypical antipsychotic as augmentation to antidepressants by the FDA and their results showed a strong increase in augmentation therapy after the approval [78].

Strength and weaknesses of the present study

A strength of this study is the profound and extensive set of daily medication data. Hence, a relatively detailed analysis was possible. Furthermore, a comparatively large number of patients from eight hospitals in Hesse, Germany, was included, providing a relatively representative picture of hospital care for depressive disorders in Germany.

The present study did not delineate patient-specific benefit-risk balances of prescriptions, for instance by including drug serum levels, results of electrocardiograms or individual pharmacogenetic risk factors. Therefore, it was not possible to differentiate between DDI and actually inadequate prescriptions. Neither did our study document actual ADR related to DDI, which would have required an entirely different study design and setting. However, the association between DDI and the risk of ADR is well established by several previous studies [8,16,17,68–72].

Conclusion

Most inpatients with depressive disorders receive multiple psychotropic and non-psychotropic drugs, and DDI and PIM are relatively frequent. Few drugs accounted for a large fraction of cases. Due to the high prevalence and the potentially negative outcomes, patients taking a high number of different drugs require an intensive management of their individual drug-related risk-benefit profiles.

Conflicts of interest: Independent of the present study, KD received fees from Janssen Pharmaceuticals, Inc. for her consultancy work on the Neuroscience Steering Committee. CN received lecture and consultancy fees from Janssen-Cilag and Neuraxpharm as well as fees for conducting clinical studies from Janssen-Cilag. ST has received lecture fees from Janssen-Cilag, Otsuka / Lundbeck and Servier and is a member of the Advisory Board of Otsuka and Janssen-Cilag. CH has received lecture fees from Otsuka.

Ethics vote/IRB statement: The study was approved by the ethics committee of the State Medical Association of Hesse under the file number FF116 / 2017. In accordance with the ethics approval, our retrospective study did not require individual patient consent.

Funding: Financial support for this study was provided entirely by a grant from the Innovations Funds of the German Federal Joint Committee (grant number: 01VSF16009). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.

References

- 1 James SL, Abate D, Abate KH, *et al.* Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet* 2018;**392**:1789–858. doi:10.1016/S0140-6736(18)32279-7
- 2 Cuijpers P, Sijbrandij M, Koole SL, *et al.* Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. *World Psychiatry* 2014;**13**:56–67. doi:10.1002/wps.20089
- 3 Gartlehner G, Hansen RA, Morgan LC, *et al.* Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder: An Updated Meta-analysis. *Ann Intern Med* 2011;**155**:772. doi:10.7326/0003-4819-155-11-201112060-00009
- 4 APA. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. 2019.
- 5 AWMF. S3-Leitlinie/Nationale VersorgungsLeitlinie - Unipolare Depression - Langfassung. Version 5. AWMF-Register-Nr.: nvl-005. 2015.https://www.awmf.org/uploads/tx_szleitlinien/nvl-0051_S3_Unipolare_Depression_2017-05.pdf
- 6 Fava M, Rush AJ. Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice. *Psychother Psychosom* 2006;**75**:139–53. doi:10.1159/000091771
- 7 Henssler J, Bschor T, Baethge C. Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients. *Can J Psychiatry*

2016;**61**:29–43. doi:10.1177/0706743715620411

8 Leone R, Magro L, Moretti U, *et al.* Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions: Data Mining of a Spontaneous Reporting Database in Italy. *Drug Saf* 2010;**33**:667–75. doi:10.2165/11534400-000000000-00000

9 Steinman MA, Miao Y, Boscardin WJ, *et al.* Prescribing Quality in Older Veterans: A Multifocal Approach. *J Gen Intern Med* 2014;**29**:1379–86. doi:10.1007/s11606-014-2924-8

10 Hefner G, Wolff J, Hahn M, *et al.* Prevalence and sort of pharmacokinetic drug–drug interactions in hospitalized psychiatric patients. *J Neural Transm* 2020;**127**:1185–98. doi:10.1007/s00702-020-02214-x

11 Möller H-J, Benkert O, Gastpar M, *et al.* Antidepressiva. In: Möller H-J, Benkert O, Gastpar M, *et al.*, eds. *Behandlungsleitlinie Psychopharmakotherapie*. Heidelberg: : Steinkopff 2003. 1–32. doi:10.1007/978-3-7985-1962-6_1

12 Toto S, Hefner G, Hahn M, *et al.* Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients. *J Neural Transm* 2021;**epub ahead of print**. doi:10.1007/s00702-020-02298-5

13 Khan Q, Ismail M, Haider I, *et al.* Prevalence of the risk factors for QT prolongation and associated drug–drug interactions in a cohort of medical inpatients. *J Formos Med Assoc* 2019;**118**:109–15. doi:10.1016/j.jfma.2018.01.016

14 Hefner G, Hahn M, Hiemke C, *et al.* Pharmacodynamic Drug–Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients. *J Neural Transm* 2021;**epub ahead of print**. doi:10.1007/s00702-020-02291-y

15 Wenzel-Seifert K, Wittmann M, Haen E. QTc Prolongation by Psychotropic Drugs and

the Risk of Torsade de Pointes. *Dtsch Arztebl Int* 2011;**108**:687–93.
doi:10.3238/arztebl.2011.0687

16 Kalisch Ellett LM, Pratt NL, Ramsay EN, *et al.* Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia. *J Am Geriatr Soc* 2014;**62**:1916–22.
doi:10.1111/jgs.13054

17 Pasquier M, Pantet O, Hugli O, *et al.* Prevalence and determinants of QT interval prolongation in medical inpatients: QT interval prolongation. *Intern Med J* 2012;**42**:933–40.
doi:10.1111/j.1445-5994.2011.02447.x

18 Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications: Age-related changes in pharmacokinetics and pharmacodynamics. *Br J Clin Pharmacol* 2003;**57**:6–14.
doi:10.1046/j.1365-2125.2003.02007.x

19 Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. *Dtsch Arztebl Int* 2010;**107**:543–51. doi:10.3238/arztebl.2010.0543

20 Fick DM, Cooper JW, Wade WE, *et al.* Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: Results of a US Consensus Panel of Experts. *Arch Intern Med* 2003;**163**:2716. doi:10.1001/archinte.163.22.2716

21 Hefner G, Hahn M, Toto S, *et al.* Potentially inappropriate medication in older psychiatric patients. *Eur J Clin Pharmacol* 2020;**epub ahead of print**. doi:10.1007/s00228-020-03012-w

22 Motter FR, Fritzen JS, Hilmer SN, *et al.* Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. *Eur J Clin Pharmacol* 2018;**74**:679–700. doi:10.1007/s00228-018-2446-0

- 23 WHO. *Medication Safety in Polypharmacy*. Genf: : World Health Organization 2019.
- 24 Wolff J, Gary A, Jung D, *et al*. Predicting patient outcomes in psychiatric hospitals with routine data: a machine learning approach. *BMC Med Inform Decis Mak* 2020;**20**:21. doi:10.1186/s12911-020-1042-2
- 25 Wolff J, *et al*. Predicting the risk of drug-drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study. *BMJ Open*; **In Press**. **DOI follows**.
- 26 Hiemke C, Bergemann N, Clement H, *et al*. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry* 2018;**51**:9–62. doi:10.1055/s-0043-116492
- 27 Grözinger M, Dragicevic A, Hiemke C, *et al*. Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine. *Pharmacopsychiatry* 2003;**36**:3–6. doi:10.1055/s-2003-38084
- 28 Mannheimer B, Bahr C von, Pettersson H, *et al*. Impact of Multiple Inhibitors or Substrates of Cytochrome P450 2D6 on Plasma Risperidone Levels in Patients on Polypharmacy: *Ther Drug Monit* 2008;**30**:565–9. doi:10.1097/FTD.0b013e31818679c9
- 29 Wójcikowski J, Pichard-Garcia L, Maurel P, *et al*. Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. *Pol J Pharmacol* 2002;**54**:407–10.
- 30 Schaller G, Jacobi A, Rotter A, *et al*. Perazine elevates clozapine serum levels by inhibiting hepatic metabolism. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;**33**:908–9. doi:10.1016/j.pnpbp.2009.04.006
- 31 Fischer M, Unterecker S, Deckert J, *et al*. Elevated clozapine serum levels in combination with perazine. *Psychopharmacology* 2013;**226**:623–5. doi:10.1007/s00213-013-

3007-y

32 Hiemke, Christoph C, Eckermann G. Kombinationstherapie/Polypharmazie - Interaktionen von Psychopharmaka. *Arzneimitteltherapie* 2014;**32**:361–70.

33 Woosley R, Romero K. Crediblemeds.org QT drugs List. AZCERT, Inc. 2020.<https://crediblemeds.org/>

34 Romero K, Woosley RL. Clarification to the www.qtdrugs.org updated lists. *Pharmacoepidemiol Drug Saf* 2009;**18**:423–4. doi:10.1002/pds.1727

35 Chew ML, Mulsant BH, Pollock BG, *et al.* Anticholinergic Activity of 107 Medications Commonly Used by Older Adults. *J Am Geriatr Soc* 2008;**56**:1333–41. doi:10.1111/j.1532-5415.2008.01737.x

36 Lertxundi U, Domingo-Echaburu S, Hernandez R, *et al.* Expert-based drug lists to measure anticholinergic burden: similar names, different results: Scores to measure anticholinergic burden. *Psychogeriatrics* 2013;**13**:17–24. doi:10.1111/j.1479-8301.2012.00418.x

37 Laux G, Dietmaier O. Was sind Psychopharmaka? In: *Psychopharmaka*. Berlin, Heidelberg: : Springer Berlin Heidelberg 2018. 11–3. doi:10.1007/978-3-662-55576-7_2

38 Masnoon N, Shakib S, Kalisch-Ellett L, *et al.* What is polypharmacy? A systematic review of definitions. *BMC Geriatr* 2017;**17**:230. doi:10.1186/s12877-017-0621-2

39 Agresti A, Coull BA. Approximate Is Better than “Exact” for Interval Estimation of Binomial Proportions. *The American Statistician* 1998;**52**:119–26. doi:10.2307/2685469

40 Prisco V, Iannaccone T, Capuano A, *et al.* Drug safety warnings in psychiatry: Adverse drug reactions’ signaling from 2002 to 2014. *Eur Psychiatr* 2017;**41**:S758–S758.

doi:10.1016/j.eurpsy.2017.01.1420

41 Davis KAS, Farooq S, Hayes JF, *et al.* Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health. *The Lancet Psychiatry* 2020;**7**:363–70. doi:10.1016/S2215-0366(19)30298-6

42 Cipriani A, Furukawa TA, Salanti G, *et al.* Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet* 2018;**391**:1357–66. doi:10.1016/S0140-6736(17)32802-7

43 Gelenberg AJ, Freeman MP, Markowitz JC, *et al.* Practice guideline for the treatment of patients with major depressive disorder. 3rd ed.

44 Fournier JC, DeRubeis RJ, Hollon SD, *et al.* Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis. *JAMA* 2010;**303**:47. doi:10.1001/jama.2009.1943

45 Kirsch I, Deacon BJ, Huedo-Medina TB, *et al.* Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med* 2008;**5**:e45. doi:10.1371/journal.pmed.0050045

46 Bockting CLH, ten Doesschate MC, Spijker J, *et al.* Continuation and Maintenance Use of Antidepressants in Recurrent Depression. *Psychother Psychosom* 2008;**77**:17–26. doi:10.1159/000110056

47 DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. *Nat Rev Neurosci* 2008;**9**:788–96. doi:10.1038/nrn2345

- 48 de Mello MF, de Jesus Mari J, Bacaltchuk J, *et al.* A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. *Eur Arch Psychiatry Clin Neurosci* 2005;**255**:75–82. doi:10.1007/s00406-004-0542-x
- 49 UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *The Lancet* 2003;**361**:799–808. doi:10.1016/S0140-6736(03)12705-5
- 50 Nahas Z, Marangell LB, Husain MM, *et al.* Two-Year Outcome of Vagus Nerve Stimulation (VNS) for Treatment of Major Depressive Episodes. *J Clin Psychiatry* 2005;**66**:1097–104. doi:10.4088/JCP.v66n0902
- 51 Dodd S, Horgan D, Malhi GS, *et al.* To combine or not to combine? A literature review of antidepressant combination therapy. *Journal of Affective Disorders* 2005;**89**:1–11. doi:10.1016/j.jad.2005.08.012
- 52 Blier P, Ward HE, Tremblay P, *et al.* Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. *Am J Psychiatry* 2010;**167**:281–8. doi:10.1176/appi.ajp.2009.09020186
- 53 Ravindran LN, Eisfeld BS, Kennedy SH. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. *J Clin Psychopharmacol* 2008;**28**:107–8. doi:10.1097/JCP.0b013e318160d609
- 54 Meagher D, Hannan N, Leonard M. Duloxetine-mirtazapine combination in depressive illness: The case for Limerick “rocket fuel.” *Ir J Psychol Med* 2006;**23**:116–8. doi:10.1017/S0790966700009782
- 55 Hannan N, Hamzah Z, Akinpeloye HO, *et al.* Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. *J Psychopharmacol* 2007;**21**:161–4.

doi:10.1177/0269881107065738

56 Malhi GS, Ng F, Berk M. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. *Aust N Z J Psychiatry* 2008;**42**:346–9. doi:10.1080/00048670701881587

57 Tundo A, de Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. *World J Psychiatry* 2015;**5**:330–41. doi:10.5498/wjp.v5.i3.330

58 Nelson JC, Papakostas GI. Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials. *AJP* 2009;**166**:980–91. doi:10.1176/appi.ajp.2009.09030312

59 Hermes EDA, Sernyak M, Rosenheck R. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. *Sleep* 2013;**36**:597–600. doi:10.5665/sleep.2554

60 Hajak G, Rodenbeck A, Voderholzer U, *et al.* Doxepin in the Treatment of Primary Insomnia: A Placebo-Controlled, Double-Blind, Polysomnographic Study. *J Clin Psychiatry* 2001;**62**:453–63. doi:10.4088/JCP.v62n0609

61 Hirsch S, Steinert T. The Use of Rapid Tranquilization in Aggressive Behavior. *Deutsches Aerzteblatt Online* Published Online First: 28 June 2019. doi:10.3238/arztebl.2019.0445

62 Farahani A, Correll CU. Are Antipsychotics or Antidepressants Needed for Psychotic Depression?: A Systematic Review and Meta-Analysis of Trials Comparing Antidepressant or Antipsychotic Monotherapy With Combination Treatment. *J Clin Psychiatry* 2012;**73**:486–96. doi:10.4088/JCP.11r07324

- 63 Wijkstra J, Lijmer J, Burger H, *et al.* Pharmacological treatment for psychotic depression. *Cochrane Database Syst Rev* 2015;:CD004044. doi:10.1002/14651858.CD004044.pub4
- 64 Rush AJ, South C, Jha MK, *et al.* What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. *J Clin Psychiatry* 2020;**81**. doi:10.4088/JCP.19m12949
- 65 Schosser A, Serretti A, Souery D, *et al.* European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings. *European Neuropsychopharmacology* 2012;**22**:453–68. doi:10.1016/j.euroneuro.2012.02.006
- 66 Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. *Acta Psychiatrica Scandinavica* 2010;**121**:174–9. doi:10.1111/j.1600-0447.2009.01458.x
- 67 Ruhé HG, Huyser J, Swinkels JA, *et al.* Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder: A Systematic Review. *J Clin Psychiatry* 2006;**67**:1836–55. doi:10.4088/JCP.v67n1203
- 68 Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. *J R Soc Med* 2000;**93**:457–62. doi:10.1177/014107680009300903
- 69 Lupu AM, Clinebell K, Gannon JM, *et al.* Reducing Anticholinergic Medication Burden in Patients With Psychotic or Bipolar Disorders. *J Clin Psychiatry* 2017;**78**:e1270–5. doi:10.4088/JCP.16m11269
- 70 Nosè M, Bighelli I, Castellazzi M, *et al.* Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. *Epidemiol Psychiatr Sci* 2016;**25**:532–40. doi:10.1017/S2045796015000906

71 Beach SR, Celano CM, Noseworthy PA, *et al.* QTc Prolongation, Torsades de Pointes, and Psychotropic Medications. *Psychosomatics* 2013;**54**:1–13. doi:10.1016/j.psych.2012.11.001

72 Hasnain M, Vieweg WVR. QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review. *CNS Drugs* 2014;**28**:887–920. doi:10.1007/s40263-014-0196-9

73 de Leon J. Why Do You Keep Telling Me That Drug-Drug Interactions Are Important in Psychopharmacology When I Do Not See Them in My Clinical Practice?: My Failure to Convince Clinicians. *J Clin Psychopharmacol* 2019;**39**:1–4. doi:10.1097/JCP.0000000000000924

74 English BA, Dortch M, Ereshefsky L, *et al.* Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. *Curr Psychiatry Rep* 2012;**14**:376–90. doi:10.1007/s11920-012-0284-9

75 Liefwaard L, Chen C. Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability. *Therapeutic Drug Monitoring* 2015;**37**:641–8. doi:10.1097/FTD.0000000000000194

76 Rhee TG, Rosenheck RA. Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders. *Journal of Affective Disorders* 2019;**252**:450–7. doi:10.1016/j.jad.2019.04.018

77 Cascade EF, Kalali AH, Blier P. Treatment of depression: antidepressant monotherapy and combination therapy. *Psychiatry (Edgmont)* 2007;**4**:25–7.

78 Lenderts S, Kalali A. Treatment of depression: an update on antidepressant monotherapy and combination therapy. *Psychiatry (Edgmont)* 2009;**6**:15–7.




Fig 1 Number of different drugs per day. Boxes show the range between the 25th percentile and the 75th percentile. The horizontal line within the boxes shows the median. The numbers in squares show the arithmetic mean.




Fig 2 TOP 10 drug groups. ATC-Code are provided in brackets. Acid Related Dis.: Drugs for acid related disorders, Antithrombotic: Antithrombotic agents, Antianemic: Antianemic preparations, Beta Blocking: Beta blocking agents, Renin-Angiotensin Sys.: Agents acting on the renin-angiotensin System, Antiinfla. & -rheum.: Antiinflammatory and antirheumatic products, Hypnotics & Sedat.: Hypnotics and sedatives.




Fig 3 Frequency of antidepressant and antipsychotic drugs and their combinations. (A+B) Augmentation: Combination of antidepressant and antipsychotic drugs. Combination AD: Combination of more than one antidepressant drug. Combination AP: Combination of more than one antipsychotic drug. Mono: Use of a single antidepressant or antipsychotic drug. None: Neither an antidepressant drug nor an antipsychotic drug. (A) Number of days with the respective drug or drug combination and the proportion in total patient days. Only intersections with at least 2% of total days are shown. SSRI: Selective serotonin reuptake inhibitors, atyp. AP: atypical antipsychotics, SNRI: Serotonin and norepinephrine reuptake inhibitors, mid-low AP: middle- and low-potency antipsychotics. None: Patient did not receive an antidepressant or an antipsychotic drug at that day. NDRI: Norepinephrine–dopamine reuptake inhibitor (B) Total number of days with the respective drug and the proportion in total patient days. Double counting of days is possible. Combinations are counted within and between classes of antidepressants and antipsychotics. (C) Total number of cases with the respective treatment regime and proportion in total cases. None: Patient did not receive an antidepressant or an antipsychotic drug. Mono AD: Patient received one antidepressant drug. Switch/Trial: Patient received more than one antidepressant or antipsychotic drug but not more than three days in combination. Combi AD: Patient received more than one antidepressant drug in combination more than three days. Augmentation AD/AP: Patient received a combination of antidepressant and antipsychotic drugs more than three days. Only AP: Patient received antipsychotic drugs but no antidepressant drugs.




Fig 4 Mean number of drugs per day and the proportion of cases with at least one DDI or PIM during their stay CYP450-Interaction: Pharmacokinetic cytochrome P450 (CYP)-mediated drug-drug interaction. QT-Combi.: A combination of at least two drugs on the same day with known or possible risk of TdP. Antichol. Combi.: A combination of at least two drugs on the same day with at least moderate anticholinergic activity. PIM: Potentially inappropriate medication in the elderly. >64: Number of cases of more than 64 years of age at admission.




Fig 5 TOP-20 drugs and drug combinations ranked by proportion of affected cases in total number of cases Double counting is possible, i.e. a case can have received several drugs or combinations of drugs. CYP450-Interaction: Pharmacokinetic cytochrome P450 (CYP)-mediated drug-drug interaction. QT-Combi.: A combination of at least two drugs on the same day with known/high or possible/moderate risk of TdP. Antichol. Combi.: A combination of at least two drugs on the same day with at least moderate anticholinergic activity. PIM: Potentially inappropriate medication in the elderly. Poss: Possible. Mod: Moderate.




Fig 6 Patient-specific risk factors for DDI and PIM Circles show odds ratios of a multivariate logistic regression. These ratios reflect the multiplicative effect per influencing variable, i.e., for example, the risk of receiving at least one PIM increased by 18% for each additional drug taken, controlled for the other variables in the model. The values in brackets show the 95% confidence interval. Confidence intervals that do not include 1 show a statistically significant effect. CYP450-Interaction: Pharmacokinetic cytochrome P450 (CYP)-mediated drug-drug interaction. QT-Combi.: A combination of at least two drugs on the same day with known or possible risk of TdP. Antichol. Combi.: A combination of at least two drugs on the same day with at least moderate anticholinergic activity. PIM: Potentially inappropriate medication in the elderly. Mod.: Moderate.